RecruitingPersonalized Neoantigen Vaccine in Combination With Anti-PD-1 Inhibitors in Standard Therapy-Failed and Adjuvant TherapyGastrointestinal Tumors
Personalized mRNA Cancer Vaccine for Gastrointestinal Solid Tumor Treatment
Eligible age
18+ yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Evaluating the efficacy and safety of Neoantigen Personalized Cancer Vaccine deepGeneAI-001 in combination with Sintilimab in the treatment of Gastrointestinal Solid Tumors
Sponsor: Ruijin Hospital
You may qualify if…
- ✓ 1. Voluntarily signs the informed consent form, and has good compliance.
- ✓ 2. Male or female, aged 18 years or older.
- ✓ 3. Patients with advanced gastrointestinal tumors: histologically and/or cytologically confirmed recurrent or metastatic gastrointestinal solid tumors not amenable to surgical or local curative treatment, with at least one measurable lesion as defined by RECIST v1.1. Eligible patients must have experienced disease progression following standard antitumor therapy or be unable or unwilling to receive standard treatment.
- ✓ Patients with resectable gastrointestinal solid tumors for adjuvant treatment: tumors must be confirmed as completely resected (R0 or R1) by postoperative histopathology, with no prior neoadjuvant therapy, and assessed as fully resectable by imaging.
- ✓ 4. Neoantigen load requirement: at least 10 predicted neoantigen epitopes.
- ✓ 5. The subject must have a tumor lesion suitable for repeated sampling for sequencing and immune testing. Fresh or archived tumor tissue is required, preferably from surgical or core needle biopsy (CNB) samples, including both tumor and 2-3 soybean-sized peritumoral tissues. Paraffin blocks or at least 10-20 unstained tumor tissue sections (4-6 μm thick) with tumor content \>20% are acceptable. If the subject cannot provide suitable samples but meets other inclusion/exclusion criteria, the investigator may still consider enrollment.
- ✓ 6. ECOG performance status of 0 or 1.
- ✓ 7. Life expectancy of at least 6 months.
You may not qualify if…
- ✕ 1. Known allergy or hypersensitivity to any investigational drug or its components used in this study.
- ✕ 2. Use of high-dose corticosteroids (\>10 mg/day prednisone or equivalent) or other immunosuppressive medications within 14 days before the first dose of study drug.
- ✕ 3. Receipt of the following therapies or interventions within 28 days before the first dose of study drug:
- ✕ 1. Participation in an interventional clinical study;
- ✕ 2. Major surgery or traumatic injury, or expected to undergo major surgery during the study (minor procedures such as core needle biopsy or placement of a vascular access device within 7 days before the first dose are permitted);
- ✕ 3. Vaccination with a live attenuated vaccine, or planned vaccination during the study or within 5 months after the last dose of study treatment;
- ✕ 4. Systemic antitumor therapy (including chemotherapy, small molecule targeted therapy, antibody therapy, cellular immunotherapy, hormonal therapy), or local antitumor therapy (e.g., radiotherapy). Palliative radiotherapy for bone metastases completed \>2 weeks before baseline tumor assessment is allowed. Also includes prior treatment with systemic immune-stimulating agents (e.g., interferons or interleukin-2).
- ✕ 4. Presence of severe chronic or active infection within 28 days before the first dose, including but not limited to hospitalization due to infection, sepsis, or severe pneumonia, or any active infection deemed to compromise patient safety by the investigator. Systemic antibiotic treatment within 2 weeks before study start.
Source: ClinicalTrials.gov · NCT07067385 · last updated 2025-07-16